Sagimet Biosciences (SGMT) Share-based Compensation (2022 - 2026)

Sagimet Biosciences' Share-based Compensation history runs 5 years deep, the most recent figure standing at $9.9 million for Q1 2026.

• On a quarterly basis, Share-based Compensation rose 572.55% year-over-year to $9.9 million in Q1 2026; TTM through Mar 2026 was $9.9 million, a 1048.49% increase from a year earlier, with the FY2025 full-year figure at $8.3 million, down 2.35% from the prior year.
• Share-based Compensation climbed to $9.9 million in Q1 2026 per SGMT's latest filing, from $9.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $9.9 million in Q1 2026 and bottomed at -$3.6 million in Q4 2024.
• The 5-year median for Share-based Compensation is $1.1 million (2023), against an average of $1.8 million.
• Across the five-year window, Share-based Compensation sank 374.98% in 2024 and surged 572.55% in 2026, its largest moves.
• Year by year, Share-based Compensation stood at $721000.0 in 2022, then surged by 81.83% to $1.3 million in 2023, then sank by 374.98% to -$3.6 million in 2024, then soared by 360.75% to $9.4 million in 2025, then grew by 5.32% to $9.9 million in 2026.
• Per Business Quant, the three latest SGMT Share-based Compensation figures stand at $9.9 million (Q1 2026), $9.4 million (Q3 2025), and $1000.0 (Q2 2025).